| In millions, except per share items | Mar-31-18 | Dec-31-17 | Sep-30-17 | Jun-30-17 | Mar-31-17 | Dec-31-16 | Sep-30-16 | Jun-30-16 |
| | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues: |
| Impax Generics | 498.1 | 549.1 | 575.4 | 599.6 | 570.4 | 606.3 | 693.9 | 699.3 |
| Impax Specialty Pharma | 235.7 | 226.7 | 215.9 | 213.2 | 212.9 | 218.1 | 214.2 | 202.0 |
| Total revenues | 733.7 | 775.8 | 791.3 | 812.8 | 783.3 | 824.4 | 908.1 | 901.3 |
| Revenue growth [+] | -6.3% | -5.9% | -12.9% | -9.8% | -16.9% | -4.2% | 28.0% | 39.4% |
| Impax Generics | -12.7% | -9.4% | -17.1% | -14.3% | -24.2% | -14.7% | 15.3% | 23.3% |
| Impax Specialty Pharma | 10.7% | 3.9% | 0.8% | 5.6% | 11.7% | 45.9% | 99.1% | 154.0% |
| Cost of goods sold | 527.0 | 535.1 | 537.7 | 515.8 | 484.2 | 486.9 | 517.9 | 508.5 |
| Gross profit | 206.8 | 240.7 | 253.6 | 297.0 | 299.1 | 337.5 | 390.2 | 392.7 |
| Gross margin | 28.2% | 31.0% | 32.0% | 36.5% | 38.2% | 40.9% | 43.0% | 43.6% |
| Selling, general and administrative [+] | 226.5 | 216.3 | 209.8 | 211.3 | 204.6 | 201.8 | 200.8 | 192.0 |
| Sales and marketing | 162.5 | | 152.3 | 153.7 | 147.0 | | 144.2 | 135.5 |
| General and administrative | | 64.0 | | | | 57.6 | | |
| Research and development | 70.7 | 80.8 | 85.7 | 90.0 | 83.9 | 80.5 | 80.0 | 78.5 |
| Other operating expenses | -289.0 | -328.1 | -241.8 | 30.8 | 45.9 | 0.8 | 245.3 | -42.3 |
| EBITDA [+] | 300.3 | 381.1 | 310.5 | 70.8 | 63.1 | 142.8 | -52.7 | 239.8 |
| EBITDA growth | 376.0% | 166.9% | -688.8% | -70.5% | -75.0% | -29.3% | -152.2% | 171.8% |
| EBITDA margin | 40.9% | 49.1% | 39.2% | 8.7% | 8.1% | 17.3% | -5.8% | 26.6% |
| Depreciation | 36.0 | 41.1 | 42.2 | 36.1 | 33.5 | 31.9 | 30.5 | 30.8 |
| EBITA | 264.2 | 340.0 | 268.2 | 34.7 | 29.6 | 111.0 | -83.2 | 209.0 |
| EBITA margin | 36.0% | 43.8% | 33.9% | 4.3% | 3.8% | 13.5% | -9.2% | 23.2% |
| Amortization of intangibles | 65.6 | 68.4 | 68.4 | 69.8 | 64.9 | 56.5 | 52.6 | 44.5 |
| EBIT [+] | 198.6 | 271.7 | 199.9 | -35.1 | -35.3 | 54.5 | -135.8 | 164.5 |
| EBIT growth | -662.7% | 398.8% | -247.2% | -121.3% | -119.8% | -59.2% | -417.4% | 303.9% |
| EBIT margin | 27.1% | 35.0% | 25.3% | -4.3% | -4.5% | 6.6% | -15.0% | 18.3% |
| Non-recurring items [+] | | 674.4 | 559.8 | 560.5 | | 548.6 | 63.7 | |
| Asset impairment | | 664.1 | 540.9 | | | 541.6 | -0.1 | |
| Loss (gain) on sale of assets | | 17.2 | | 11.9 | | | | |
| Loss on contingent liability | | -31.0 | | | | | | |
| Interest expense, net [+] | 52.6 | 52.1 | 51.4 | 49.0 | 43.9 | 38.6 | 33.3 | 30.3 |
| Interest expense | 53.7 | 53.3 | 52.8 | 50.2 | 45.3 | 40.4 | 35.0 | 32.1 |
| Interest income | | 1.1 | 1.4 | 1.3 | | 1.8 | 1.7 | 1.7 |
| Other income (expense), net [+] | 6.7 | 3.9 | -0.6 | 1.2 | 1.4 | -43.5 | -59.3 | -17.2 |
| Gain (loss) on sale of assets | -0.4 | | | | | | | |
| Litigation settlement | 85.5 | | | | 1.1 | | | |
| Gain (loss) on debt retirement | | | | | -1.2 | | | |
| Other | -7.9 | -9.9 | -12.5 | -13.1 | -3.3 | -1.4 | -0.4 | -0.1 |
| Pre-tax income | -521.7 | -451.0 | -411.9 | -643.3 | -626.4 | -576.3 | -292.0 | 53.2 |
| Income taxes | -19.9 | 18.3 | 35.9 | -65.6 | -66.3 | -104.3 | -111.0 | 19.1 |
| Tax rate | 3.8% | -4.1% | -8.7% | 10.2% | | | 38.0% | 35.9% |
| Net income | -501.8 | -469.3 | -447.8 | -577.8 | -560.1 | -472.0 | -181.0 | 34.1 |
| Net margin | -68.4% | -60.5% | -56.6% | -71.1% | -71.5% | -57.3% | -19.9% | 3.8% |
| |
| Basic EPS [+] | ($6.97) | ($6.53) | ($6.25) | ($8.07) | ($7.85) | ($6.63) | ($2.56) | $0.48 |
| Growth | -11.2% | -1.6% | 143.9% | -1766.1% | -1669.8% | -1281.4% | -738.9% | 333.9% |
| Diluted EPS [+] | ($6.97) | ($6.53) | ($6.25) | ($8.07) | ($7.85) | ($6.63) | ($2.54) | $0.48 |
| Growth | -11.2% | -1.6% | 145.9% | -1797.8% | -1699.8% | -1304.2% | -745.7% | 333.2% |
| |
| Shares outstanding (basic) [+] | 72.0 | 71.9 | 71.7 | 71.6 | 71.4 | 71.1 | 70.7 | 70.3 |
| Growth | 0.9% | 1.0% | 1.4% | 1.8% | 2.2% | 2.5% | 2.3% | 2.4% |
| Shares outstanding (diluted) [+] | 72.0 | 71.9 | 71.7 | 71.6 | 71.4 | 71.1 | 71.3 | 71.6 |
| Growth | 0.9% | 1.0% | 0.6% | -0.1% | 0.2% | 0.5% | 1.2% | 2.5% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |